About
Optellum is a commercial-stage lung health company providing Artificial Intelligence decision support software that assists physicians in early diagnosis and optimal treatment for their patients. The company was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, when chances of cure are the highest.
Our product is Optellum Virtual Nodule Clinic which identifies, tracks and manages patients with Lung Cancer Prediction, which stratifies and assists diagnosis, supporting clinical decision making. Virtual Nodule Clinic is the world’s first and only AI-based lung cancer decision support software and is both FDA and CE-mark cleared. Optellum has partnerships with GE Healthcare and the Johnson & Johnson Lung Cancer Initiative.
Optellum’s roadmap extends beyond lung cancer diagnosis and treatment to other deadly diseases of the lungs, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Optellum has headquarters at the Oxford Centre for Innovation in Oxford, United Kingdom and a U.S. office at the Texas Medical Center in Houston, TX.
For more information, visit optellum.com, or follow us LinkedIn and Twitter.
Key Facts
• Optellum’s technology has been independently validated by world-leading lung cancer experts in the British Medical Journal: Thorax (March 2020) and the American Journal of Respiratory and Critical Care Medicine (April 2020). These are the leading respiratory medicine journals. • Clinical trials have shown that the Optellum Lung Cancer Prediction model significantly improved diagnostic accuracy compared to any existing clinical risk model. When used by pulmonologists and radiologists, the readers showed improvement in both sensitivity and specificity in determining the risk of a lung nodule being cancerous.
Successes in UK/NHS
Externally validated and NIHR-funded clinical trial in Oxford University Hospitals NHS Foundation Trust, the Leeds Teaching Hospitals, and Nottingham University Hospitals NHS Trust. We have been the lead industry partner on research grants with Oxford University Hospitals NHS Foundation Trust totally over £20 million. Optellum Virtual Nodule Clinic, including its proprietary artificial intelligence lung cancer prediction solution, has achieved CE certification under the European Union’s Medical Device Regulation. The platform is currently being piloted at ten NHS hospitals as part of DOLCE – a landmark research project led by Professor David Baldwin, who is Honorary Professor of Medicine at the University of Nottingham, and Consultant Physician at Nottingham University Hospitals NHS Trust. The project is part of the NHS AI Lab’s £140 million AI in Health and Care Award to accelerate the testing and evaluation of AI in the NHS so patients can benefit from faster and more personalised diagnosis and greater efficiency in screening services. Optellum is also the lead industrial partner in the UK’s DART (Data Using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases) consortium, working with NHS England’s Targeted Lung Health Check programme which will provide lung cancer screening to approximately 600,000 eligible people. Optellum was also recently featured in Health Education England’s AI Roadmap Report which reviewed the preparedness of the NHS for the implementation of new AI technologies and the impact these technologies will have on workforce, the patient pathway and wider system performance.Company details
Solutions
Augmenting healthcare professionals
Providing advanced screening and diagnostics
Specialism
Decision Support and treatment planning
Specialised diagnostics
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.optellum.comMarkets already exporting to
UK and USA
Desired Markets
Europe, Asia Pacific
Desired customer types
Academic Medical Centres, Community Hospitals, hospital systems, health systems, private medical centres and clinics: especially those with an interest in the diagnosis and treatment of lung disease.